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Abstract Diabetic patients have a higher fracture risk than
expected by their bone mineral density (BMD). Poor bone
quality is the most suitable and explainable cause for the ele-
vated fracture risk in this population. Advanced glycation end
products (AGEs), which are diverse compounds generated via
a non-enzymatic reaction between reducing sugars and amine
residues, physically affect the properties of the bone material,
one of a component of bone quality, through their accumula-
tion in the bone collagen fibers. On the other hand, these
compounds biologically act as agonists for these receptors
for AGEs (RAGE) and suppress bone metabolism. The con-
centrations of AGEs and endogenous secretory RAGE, which
acts as a Bdecoy receptor^ that inhibits the AGEs-RAGE sig-
naling axis, are associated with fracture risk in a BMD-
independent manner. AGEs are closely associated with the
pathogenesis of this unique clinical manifestation through
physical and biological mechanisms in patients with diabetes
mellitus.
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Introduction
Diabetic patients have a higher fracture risk than ex-
pected by their bone mineral density (BMD) [1–4].
Bone strength consists of BMD and bone quality [5],
suggesting that increased bone fragility in this popula-
tion is, in part, caused by a deterioration of bone qual-
ity. Bone quality, conceptually, is divided into geomet-
rical properties and material properties [6]. The former
indicates the morphological characteristics of bone.
Some studies indicate that aggravation of the structural
properties assessed by high-resolution peripheral quanti-
tative computed tomography (HR-pQCT) and trabecular
bone score (TBS) is involved in bone fragility [7–9].
The material properties of bone, another component of
bone quality, are regulated by tissue turnover, cellular
activity, and oxidative stress and glycation [10].
Advanced glycation end products (AGEs) are diverse
compounds that are generated via a non-enzymatic reac-
tion between reducing sugars and the amine residues on
proteins, lipids, and nucleic acids. Growing evidence of
fracture risk in patients with diabetes mellitus indicates
the crucial roles of AGEs in aggravating bone fragility,
as in the cases of the progression of classical diabetic
complications [11]. This review focuses on the material
properties and summarizes the association between
AGEs and bone fragility in patients with diabetes.
Bone Mineral Density in Diabetic Patients
The measurement of BMD is an established method for
assessing bone strength. An association between decreased
BMD, as measured by dual-energy X-ray absorptiometry
(DXA), and the fracture rate was observed in postmenopausal
women with osteoporosis. In 1991, osteoporosis was defined
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as Ba disease that is characterized by low bone mass,
microarchitectural deterioration of bone tissue leading to en-
hanced bone fragility, and consequent increase in fracture
risk^ [12], and the diagnostic criteria for osteoporosis, which
were primarily based on BMD, were established. In contrast,
there was less information on the BMD values of diabetic
patients. Diabetes mellitus is classified into two major types:
type 1 diabetes mellitus (T1DM), which is caused by a loss of
the ability to secrete insulin that possesses an anabolic action
on bone, and type 2 diabetes mellitus (T2DM), which de-
velops in the presence of underlying insulin resistance. In
T1DM, BMD measured in the femoral neck or the lumbar
vertebrae has been reported to be significantly lower than
the respective value in age- and body mass index-matched
non-diabetic subjects [13, 14]; these findings were consistent-
ly confirmed in other reports [15, 16]. A meta-analysis pub-
lished in 2007 showed that the BMD z scores (the age-
adjusted BMD) of hip and spine in T1DM patients were lower
than the scores in non-diabetic participants [1]. In contrast, the
BMD values at these sites in T2DM patients were inconsis-
tent; early reports with a small number of patients showed that
the BMD values were lower than, equivalent to, or higher than
the values in the control groups [17–20]. However, successive
reports from large-scale studies indicated that the BMD values
in these subjects were significantly higher than the values in
non-diabetic populations [21, 22]. The meta-analysis of these
studies revealed that the BMD z scores in T2DM patients were
higher than the scores in the non-diabetic population, unlike
the T1DM patients [1].
The Risk of Fracture in Diabetic Patients
The relationship between the presence of diabetes and
risk of fracture has been investigated by the clinical
type of diabetes. In patients with T1DM, the risk of
hip fractures has been reported to be significantly higher
in female patients compared with non-diabetic subjects
after adjusting for confounding factors [23, 24]. Two
meta-analyses confirmed the consistent relationship be-
tween the presence of diabetes and risk of fracture [1,
2]. In contrast, the findings obtained from the patients
with T2DM have confused us for a long time. Some
reports indicated that the risk of hip fractures is in-
creased in T2DM. However, others showed the opposite
results. Two meta-analyses concluded that the risk of
hip fracture in subjects with T2DM is significantly
higher than the risk in non-diabetic subjects, although
their BMD was higher than the control group [1, 2].
Taken together, these findings suggest that diabetes
mellitus is an underlying disease that causes secondary
osteoporosis because the risk of fracture is increased in
diabetic patients, irrespective of their diabetic clinical
type.
AGEs and Bone Fragility in Diabetes
(a) Physical effects of AGEs on bone fragility
AGE is a generic name for the various products formed
fromAmadori compounds by spontaneous dehydration, trans-
position, condensation, and oxidation reactions. Amadori
compounds are generated from a non-enzymatic condensation
reaction known as the Maillard reaction between amino
groups and carbonyl groups, such as amino acid and reducing
sugars, respectively. Thus, proteins with long half-lives, such
as collagen, have more opportunities for their lateral chains to
become glycated. Type I collagen is considered a major deter-
minant factor for the material properties of bone strength be-
cause it is a prominent protein component of bone matrix.
Collagen fibers are built from collagen molecules that are
connected to each other through crosslinking at genetically
determined site by specific enzymes, such as lysine hydroxy-
lase and lysyl oxidase [25, 26]. Enzymatic crosslinking con-
tributes to the improvements in tissue strength by changing the
material properties of bone, such as increasing collagen stiff-
ness [27, 28].
On the other hand, it is possible that non-enzymatic
crosslinking of collagen occurs as a ubiquitous glycation
process. Pentosidine (PEN) and carboxymethyl lysine
(CML) are well-recognized AGEs that possess lysine or
arginine residues. Because these residues in collagen fi-
bers are used as precursor substances for the formation of
these AGEs [29], PEN and CML are non-enzymatically
produced in collagen fibers as crosslinked and non-
crosslinked types of AGEs, respectively. In contrast to
the formation of enzymatic crosslinks, an increase in
non-enzymatic crosslinking by AGEs, including PEN, de-
teriorates bone strength. Several ex vivo studies obtained
from human samples indicate that the PEN content in
cancellous bone specimens from the tibia, cortical bone
samples from the femoral mid-shaft and tibial mid-shaft,
and trabecular bone particles from the vertebrae are in-
versely associated with ultimate strain, ultimate stress,
and fracture toughness [30–33], with the exception of
one report [34]. Indeed, the bone PEN content obtained
from non-diabetic patients with hip fracture is significant-
ly increased compared with non-diabetic patients without
fracture in the clinical setting [35, 36], suggesting that an
increase in the non-enzymatic crosslinked type of AGEs
in collagen fibers is a well-established cause of the dete-
rioration of bone strength. The pre-yield mechanical
change in bone tissue is dominantly determined by its
mineral composition; in contrast, the post-yield mechani-
cal feature is defined by the organic matrix [37]. Indeed,
several studies of non-diabetic subjects revealed that in-
creased AGEs crosslinking was associated with reduced
post-yield properties and toughness [31, 32, 38–41].
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These findings suggest that AGEs potentially disturb bone
strength partially through the physical influence of the
excess collagen crosslinking.
The physical effects of AGEs on bone fragility are
more evident in diabetic patients than in non-diabetic
patients. Saito et al. showed that the bone content of
PEN, a non-enzymatic crosslinked type of AGE, is sig-
nificantly increased in spontaneously diabetic rats just
before the onset of diabetes and that bone strength mea-
sured by the three-point bending fixture test in the dia-
betic group was significantly decreased compared to the
control group [42]. Specimens obtained by iliac crest
bone biopsy in patients with T1DM showed that the
bone PEN content in subjects with fracture was signif-
icantly increased compared with subjects without frac-
ture [43••]. PEN is a potent surrogate marker for total
AGEs production because the bone PEN content reflects
the total amount of AGEs in bone [44]. Accumulation
of PEN in skin and bone exponentially increase with
age [45, 46], and these amounts may be closely related
to each other. The material strength of the bones in
patients with T2DM, as confirmed by microindentation,
was inferior to the non-diabetic subjects and was signif-
icantly and inversely associated with the levels of skin
autofluorescence [47], indicating that the bone accumu-
lation of AGEs aggravates the material properties of
bone. Cross-sectional and prospective clinical studies
showed that increased serum and urinary PEN concen-
trations were related to an increased risk of fractures in
patients with type 1 and type 2 diabetes mellitus
[48–50, 51•] (Table 1). These associations are indepen-
dent of BMD. Therefore, the bone fragility of patients
with diabetes, which cannot be assessed by BMD, is
well explained by the poor material properties of bone
caused by an increase in the levels of non-enzymatic
crosslinked type AGEs, such as PEN.
A prospective clinical study of non-diabetic subjects
showed that the circulating levels of CML are associated with
hip fracture risk [52•]. Recently, the bone content of CML, a
non-enzymatic non-crosslinked type of AGE, in a mouse
model of type 1 diabetes was significantly increased compared
with the control mice and was significantly and inversely cor-
related with macroscopic bone toughness, similar to PEN
[53]. There is no in vitro study that revealed a significant
association between an increase in the bone content of CML
and a reduction of bone strength. CML appears to be the
dominant AGE component. Therefore, the amount of CML
may reflect the amount of PEN.
(b) Biological effects of AGEs on bone fragility
AGEs also have biological effects on bone metabolism.
The receptor for AGEs (RAGE), which is presented on the
surface of specific cells, recognizes AGEs as ligands [54] and
is involved in the progression of diabetic complications,
such as diabetic nephropathy [55]. AGEs significantly
inhibit osteoblast proliferation and induce osteoblast ap-
optosis [56–59] and IGF-1 secretion [60]. Hyperglycemia
and AGEs suppress osteoblastic differentiation and min-
eralization, accompanied by enhanced RAGE expression
[61–63]. A reactive oxygen species (ROS) inhibitor and
autophagy inducer prevent AGE-induced osteoblast apo-
ptosis, indicating that the elevation of oxidative stress
and inhibition of autophagy are involved in this event
[64]. Recently, a rat model with an autograft implant
containing AGEs showed that the mineral apposition rate
(MAR), mineralized surface per bone surface (MS/BS),
and bone formation rate (BFR) were significantly re-
duced, suggesting that the AGEs that accumulated in
the matrix are also involved in the reduced bone forma-
tion in vivo [65]. These observations suggest that the
AGE-RAGE axis plays an important role in the bone
formation process. On the other hand, AGEs decreased
osteoclast-induced bone resorption and the osteoclastic
differentiation process [66]. AGEs increased the expres-
sion of the sclerostin protein, an antagonist of bone for-
mation, and decreased the expression of the RANKL
protein, an agonist of bone resorption, in osteocyte-like
MLO-Y4-A2 cells [67]. In addition, parathyroid hormone
(PTH) secretion is inhibited by AGEs and high glucose
concentrations [68, 69]. These findings suggested that
the pathogenesis of suppressed bone turnover, one of
the characteristics of bone metabolic disorders in diabe-
tes, is partially explained by increased AGE levels.
Indeed, low bone turnover and concomitant low PTH
levels are observed in patients with T2DM [70, 71] and
are associated with an elevated risk of vertebral fracture
[70]. This finding is independent of BMD, suggesting
Table 1 The association between serum or urinary pentosidine levels
and fractures in patients with diabetes
OR (95 % CI)
Vertebral fractures
Yamamoto [48] 2.50 (1.09–5.73)*
Yamamoto [49] 1.82 (1.05–3.15)*
Schwartz [50] 5.93 (2.08–16.9)**
Clinical fractures
Schwartz [50] 1.42 (1.10–1.83)**
Osteoporotic fractures
Neumann [51•] 1.02 (1.00–1.03)**
Data are expressed as odds ratio of fracture after adjustment for multiple
covariates per 1 unit increase in pentosidine. References [48–50], per
standard deviation increase; ref. [32], per 1 pmol/mL increase.
*P < 0.05; **P < 0.01
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that bone strength is deteriorated by the poor material
properties of bone due to low bone turnover caused by
elevated AGE levels because tissue turnover is one of
determinant factors of the material properties of bone
[10].
Endogenous secretory RAGE (esRAGE), which is a splic-
ing variant of RAGE that lacks the membrane-spanning por-
tion, is known to act as Bdecoy receptor,^ inhibiting RAGE on
the cell membrane from binding to AGEs outside the cell [72].
Irrespective of sex, low esRAGE values, and relatively low
esRAGE values compared to AGEs are associated with an
increased risk of vertebral fractures in a BMD-independent
manner in patients with T2DM who are older than 50 years
(Fig. 1) [49]. This finding indicates that the AGE-RAGE sig-
naling pathway is involved in an increase in bone fragility
through the deterioration of bone quality, which may be
caused by suppressed bone turnover, and indirectly suggests
that AGEs biologically act as a RAGE agonist, which is en-
gaged in bone metabolism in clinical practice. However, a
recent clinical study of middle-aged patients with T1DM
showed that esRAGE was not associated with the risk of frac-
ture [51•]. These findings suggest that the preventive correla-
tion between fracture and the esRAGE levels might be limited
to older and/or T2DM patients.
Therapeutic Effects of Anti-osteoporosis Agents
on Diabetic Patient
A few clinical studies showed that some anti-osteoporosis
agent drugs potentially prevent fractures in diabetic pa-
tients. When considering the pathological state of osteo-
porosis in diabetic patients, bone fragility in patients with
diabetes may be rescued by improving the bone formation
or material properties of bone. In the subanalysis of the
MORE study, which examined the preventive effect of
raloxifene on vertebral fracture in postmenopausal osteo-
porotic women, the risk of vertebral fracture after the
treatment in the subgroup with diabetes was lower than
that in the non-diabetic subgroup [73]. When a non-
diabetic animal with elevated PEN induced by experimen-
tal diet was treated with raloxifene, bone strength recov-
ered, presumably by decreasing the bone PEN content
[74]. Therefore, raloxifene administration to diabetic pa-
tients is expected to improve the material properties of the
bone matrix and prevent fractures. On the other hand, the
risk of fracture in diabetic patients also increases as the
BMD decreases [4]; therefore, agents that are capable of
increasing BMD may be useful in preventing fractures.
Teriparatide, the only current agent used to promote bone
formation, decreased the bone PEN content and increased
BMD in a non-diabetic animal model [75]. Teriparatide
may be useful as a treatment for osteoporosis in diabetic
patients because it could improve the bone matrix quality
by reversing the impaired bone turnover in diabetic pa-
tients. A recent study revealed that the reduction in
nonvertebral fracture incidence, increase in BMD, and
decrease in back pain by treatment with teriparatide were
similar in T2DM and non-diabetic patients [76]. On the
other hand, bisphosphonates, which suppress bone resorp-
tion, increase BMD in T2DM patients whose bone turn-
over was decreased to similar degree compared to non-
diabetic subjects [77], suggesting that these agents may
possess particular advantages in preventing fracture in
the diabetic patients with decreased BMD.
Fig. 1 The association between the serum levels of pentosidine as well as
endogenous secretory receptor for advanced glycation end products
(esRAGE) and vertebral fractures in patients with type 2 diabetes
mellitus. The data are expressed as odds ratios of vertebral fracture after
adjusting for age, body mass index, HbA1c levels, creatine levels, duration
of diabetes, and spine bone mineral density per standard deviation increase
in each factor. OR, odds ratio; CI, confidence interval; esRAGE,
endogenous secretory receptor for advanced glycation end products.
*P < 0.05; **P < 0.01. Adapted from ref. [49]
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Conclusions
The bone fragility in patients with diabetesmellitus is predom-
inantly caused by poor bone quality because BMD is not
always a useful estimate of the bone fragility of diabetic pa-
tients. AGEs are closely associated with the pathogenesis of
this unique clinical manifestation through physical and bio-
logical effects on the deterioration of the material properties of
bone. Further studies that clarify the etiologic mechanisms of
diabetic bone fragility would provide unique diagnostic
criteria and treatment strategies for this specific form of
osteoporosis.
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